Skip to Content Skip to Search

About GSK

We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.

  • £34.1bn

    Group turnover in 2021

  • 3

    global businesses

  • 300

    years of innovation

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, preventing and treating disease and keeping people well with our scientific and technical know-how and talented people.


T-cells attacking a cancer cell
Immune system T-cells attacking a cancer cell


Herpes zoster virus of shingles
Herpes zoster virus of shingles

Consumer Healthcare

Novamin, a key technology in Sensodyne
Novamin, a key technology in Sensodyne Repair and Protect

How we do it

Everyone at GSK is focused on our three long-term priorities - Innovation, Performance, Trust - underpinned by our ambition to build a more purpose and performance driven culture, aligned to our values.


We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £4.8bn

    adjusted R&D investment in 2021

  • 43

    new medicines in development at FY 2021

  • 21

    new vaccines in development at FY 2021


We deliver growth by investing effectively in our business, developing our people and executing competitively.

  • £34.1bn

    Group turnover in 2021

  • £8.8bn

    adjusted operating profit in 2021

  • £4.4bn

    free cash flow in 2021

  • £4bn

    dividends paid in 2021


We are a responsible company. We commit to use our science and technology to address health needs, make our products affordable and available and be a modern employer.

  • 78%

    employee engagement score on our latest employee survey

  • 1st

    in Access to Medicines Index since the assessment began in 2008

Key figures

Please refer to our quarterly results materials for further information on GSK’s financial performance.

Our geographies

  • £14.6bn (43%)

    US (+6% CER) sales turnover 2020

  • £8.2bn (24%)

    Europe (+1% CER) sales turnover 2020

  • £11.4bn (33%)

    International (flat CER) sales turnover 2020